Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease
Authors:
- Hiroyuki AraiHAHiroyuki Arai
- Mitsunori SugitabMSMitsunori Sugitab
- Haruko TanjiaHTHaruko Tanjia
- Makoto HiguchiaMHMakoto Higuchia
- Nobuyuki OkamuraaNONobuyuki Okamuraa
- Toshifumi MatsuiaTMToshifumi Matsuia
- Susumu HiguchicSHSusumu Higuchic
- Sachio MatsushitacSMSachio Matsushitac
- Hiroshi YoshidabHYHiroshi Yoshidab
- Hidetada SasakiaHSHidetada Sasakia
- 1 December 2001
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 172 (2) , 433-436
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive DeclineJAMA, 2000
- Cerebrospinal fluid levels of amyloid β-peptide1–42, but not tau have positive correlation with brain glucose metabolism in humansNeuroscience Letters, 1999
- Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairmentNeuroscience Letters, 1999
- Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progressionAnnals of Neurology, 1999
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- Mild cognitive impairment — an early stage of Alzheimer’s disease?1998
- Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's diseaseNeurology, 1997
- Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s DiseaseThe Journal of Neuroscience, 1996
- Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's diseaseAnnals of Neurology, 1995
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984